House oversight chair calls for investigation into PBMs' tactics to increase drug costs
In another effort to investigate pharma middlemen and their impact on healthcare costs, House Oversight Committee Chair James Comer (R-KY) is launching an investigation into pharmacy benefit managers’ (PBM) “tactics that are harming patient care and increasing costs for consumers.”
He’s one of several politicians who have called for greater transparency into PBMs, the middlemen who negotiate rebates with drugmakers in exchange for formulary coverage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.